Genelux Corp. (GNLX) is nearing a period of heightened significance in its clinical progress, with two key data readouts expected in the second half of 2025 that could reshape its development arc.
The company's proprietary oncolytic immunotherapy, Olvi-Vec, is being evaluated across multiple indications, and upcoming results may determine the viability of its systemic delivery strategy and broader therapeutic potential.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com